Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by (1,049)

Items 801–900 of 1,049

1. Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel
   Aldo Scarpa, Katarzyna O. Sikora, Matteo Fassan, Anna Maria Rachiglio, Rocco Cappellesso, Davide Antonello, Eliana Amato, Andrea Mafficini, Matilde Lambiase, Claudia Esposito et al. · 2013 · PLoS ONE
2. Immunotherapy in the treatment of non-small cell lung cancer
   Raghav Sundar, Richie Soong, Byoung Chul Cho, Julie Renee Brahmer, Ross Andrew Soo · 2014 · Lung Cancer
3. Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis
   Akihiko Kawahara, Chizuko Yamamoto, Kazutaka Nakashima, Koichi Azuma, Satoshi Hattori, Masaki Kashihara, Hisamichi Aizawa, Yuji Basaki, Michihiko Kuwano, Masayoshi Kage et al. · 2010 · Clinical Cancer Research
4. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma
   Erin Stewart, Céline Mascaux, Nhu‐An Pham, Shingo Sakashita, Jenna R. Sykes, Lucia Kim, Naoki Yanagawa, Ghassan Allo, Kota Ishizawa, Dennis Y.Q. Wang et al. · 2015 · Journal of Clinical Oncology
5. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
   Ivana Sullivan, David Planchard · 2017 · Frontiers in Medicine
6. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
   Catherine Belle Meador, Aaron N. Hata · 2020 · Pharmacology & Therapeutics
7. AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
   Yuanyuan Zhao, Gang Chen, Jianhua Chen, Li Zhuang, Yingying Du, Qitao Yu, Wu Zhuang, Yanqiu Zhao, Ming Zhou, Weidong Zhang et al. · 2023 · EClinicalMedicine
8. Nomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinoma
   Nicolas Girard, Camelia S. Sima, D. M. Jackman, Lecia Van Dam Sequist, H. Chen, James Chih‐Hsin Yang, Haoqiang Ji, Belinda A. Waltman, Rafael Rosell, Miquel Tarón et al. · 2011 · European Respiratory Journal
9. Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging
   György Marko‐Varga, Thomas E. Fehniger, Melinda Rezeli, Balázs Döme, Thomas Laurell, Ákos Végvári · 2011 · Journal of Proteomics
10. 50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer
    Heather A. Wakelee, Karen L. Kelly, Martin Joseph Edelman · 2014 · American Society of Clinical Oncology Educational Book
11. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy
    Yin-duo Zeng, Hai Liao, Tao Qin, Li Zhang, Wei-Dong Wei, Jian-zhong Liang, Fei Xu, Xiao-Xiao Dinglin, Shu-xiang Ma, Li-kun Chen · 2015 · Oncotarget
12. Strategies for modern biomarker and drug development in oncology
    Alan David Smith, Desam Roda, Timothy Anthony Yap · 2014 · Journal of Hematology & Oncology
13. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib
    Steffen Filskov Sorensen, Christina Demuth, Britta Weber, Boe Sandahl Sørensen, Peter Meldgaard · 2016 · Lung Cancer
14. EGFR G796D mutation mediates resistance to osimertinib
    Di Zheng, Min Hu, Yu Bai, Xuehua Zhu, Xuesong Lu, Chunyan Wu, Jiying Wang, Li Liu, Zheng Wang, Jian Ni et al. · 2017 · Oncotarget
15. Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
    Manzar Alam, Shoaib Alam, Anas Shamsi, Mohd Adnan, Abdelbaset Mohamed Elasbali, Waleed Abu Al‐Soud, Mousa M. Alreshidi, Yousef MohammedRabaa Hawsawi, Anitha Tippana, Visweswara Rao Pasupuleti et al. · 2022 · Frontiers in Oncology
16. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1
    Nathaniel Weygant, Dongfeng Qu, William L. Berry, Randal J. May, Parthasarathy Chandrakesan, Daniel B. Owen, Sripathi M. Sureban, Naushad Ali, Ralf Janknecht, Courtney W. Houchen · 2014 · Molecular Cancer
17. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
    Russo, Alessandro, Franchina, Tindara, Ricciardi, Giuseppina, Battaglia, Alessandra, Picciotto, Maria, Adamo, Vincenzo · 2019 · International Journal of Molecular Sciences
18. A Brief Retrospective Report on the Feasibility of Epidermal Growth Factor Receptor and KRAS Mutation Analysis in Transesophageal Ultrasound- and Endobronchial Ultrasound-Guided Fine Needle Cytological Aspirates
    Olga C.J. Schuurbiers, Monika G. Looijen-Salamon, Marjolijn J. L. Ligtenberg, Erik H.F.M. van der Heijden · 2010 · Journal of Thoracic Oncology
19. Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: The NVALT-4 Study
    Harry J.M. Groen, Hannie Sietsma, Andrew D. Vincent, Monique M. H. Hochstenbag, John W.G. van Putten, Anke van den Berg, Otilia Dalesio, Bonne Biesma, Hans J.M. Smit, Ariën Termeer et al. · 2011 · Journal of Clinical Oncology
20. A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development
    Binsheng Zhao, Geoffrey R. Oxnard, Chaya S. Moskowitz, Mark G. Kris, William J. Pao, Pingzhen Guo, Valerie W. Rusch, Marc Ladanyi, Naiyer A. Rizvi, Lawrence Howard Schwartz · 2010 · Clinical Cancer Research
21. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
    Emilio Bria, Michèle Milella, Federica Cuppone, Silvia Novello, A. Ceribelli, V. Vaccaro, Isabella Sperduti, Alain Jonathan Gelibter, Giorgio V. Scagliotti, Francesco Cognetti et al. · 2011 · Annals of Oncology
22. Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer
    Atsuko Kitamura, Waki Hosoda, Eiichi Sasaki, Tetsuya Mitsudomi, Yasushi Yatabe · 2010 · Clinical Cancer Research
23. Functional exploration of colorectal cancer genomes using Drosophila
    Erdem Bangi, Claudio Murgia, Alexander Teague, Owen James Sansom, Ross Leigh Cagan · 2016 · Nature Communications
24. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
    Mark Magdi Awad, Giulia Costanza Leonardi, Sasha Kravets, Suzanne Eleanor Dahlberg, Alexander Edward Dela Cruz Drilon, Sinead A. Noonan, D. Ross Camidge, Sai‐Hong Ignatius Ou, Daniel Botelho Costa, Shirish M. Gadgeel et al. · 2019 · Lung Cancer
25. Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost
    Chun-Nan Kuo, Yu‐Ming Liao, Li‐Na Kuo, Hui‐Ju Tsai, Wei‐Chiao Chang, Yun Yen · 2019 · Journal of the Formosan Medical Association
26. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
    Guangjian Yang, Jun Li, Haiyan Xu, Yaning Yang, Lu Yang, Fei Xu, Bing Xia, Viola Weijia Zhu, Misako Nagasaka, Yan Yang et al. · 2020 · Lung Cancer
27. Preparation of DNA from cytological material
    Annika Dejmek, Nooreldin Zendehrokh, Malgorzata Tomaszewska, Anders Edsjö · 2013 · Cancer Cytopathology
28. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials
    Liang Shi, Junfang Tang, Tong Li, Zhe Liu · 2013 · Lung Cancer
29. Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan
    Yi‐Cheng Wu, Il‐Chi Chang, Chi-Liang Wang, Tai‐Di Chen, Ya‐Ting Chen, Huiping Liu, Yen Chu, Yu-Ting Chiu, Tzu‐Hua Wu, Li-Hui Chou et al. · 2013 · PLoS ONE
30. Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma
    Shiyong Li, Yoon‐La Choi, Zhuolin Gong, Xiao Liu, Maruja E. Lira, Zhengyan Kan, Ensel Oh, Jian Wang, Jason C. Ting, X.S. Ye et al. · 2016 · Journal of Thoracic Oncology
31. Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
    Jingsi Dong, Bingjie Li, Dan Chi-Chia Lin, Qinghua Zhou, Depei Huang · 2019 · Frontiers in Pharmacology
32. Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
    Tohru Ohmori, Toshimitsu Yamaoka, Koichi Andō, Sojiro Kusumoto, Yasunari Kishino, Ryo Manabe, Hironori Sagara · 2021 · International Journal of Molecular Sciences
33. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
    Byoung Chul Cho, Dong‐Wan Kim, Alexander I. Spira, Jorge E Gomez, Eric B. Haura, Sang‐We Kim, Rachel E. Sanborn, Eun Kyung Cho, Ki Hyeong Lee, Anna Rachel Minchom et al. · 2023 · Nature Medicine
34. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
    Matthias Scheffler, Paola Di Gion, Oxana Doroshyenko, Jürgen Wolf, Uwe Fuhr · 2011 · Clinical Pharmacokinetics
35. Targeting EGFR in Lung Cancer: Current Standards and Developments
    Díaz-Serrano, Asunción, Gella, Pablo, Jiménez, Elisabeth, Zugazagoitia, Jon, Paz-Ares Rodríguez, Luis · 2018 · Drugs
36. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX ‐Lung 3
    Terufumi Kato, Hiroshige Yoshioka, Isamu Okamoto, Akira Yokoyama, Toyoaki Hida, Takashi Seto, Katsuyuki Kiura, Dan Massey G, Yoko Seki, Nobuyuki Yamamoto · 2015 · Cancer Science
37. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
    Shunichi Sugawara, Satoshi Oizumi, Koichi Minato, Toshiyuki Harada, Akira Inoue, Yasuko Fujita, Makoto Maemondo, Hirohisa Yoshizawa, Ken‐ichi Ito, Akihiko Gemma et al. · 2015 · Annals of Oncology
38. Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges
    David A. Reardon, Patrick Yung Wen, Ingo K. Mellinghoff · 2014 · Neuro-Oncology
39. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going
    Alessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, Valeria Smiroldo, M. Picciotto, Mariangela Zanghì, Christian Diego Rolfo, Vincenzo Adamo · 2017 · Critical Reviews in Oncology/Hematology
40. Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort
    Written on behalf of AME Lung Cancer Collaborative Group, Yong Song, Chengping Hu, Zhanhong Xie, Lin Wu, Zhengfei Zhu, Chuangzhou Rao, Li Liu, Yuan Chen, Naixin Liang et al. · 2020 · Translational Lung Cancer Research
41. Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer
    M. Fakih, M. Vincent · 2010 · Current Oncology
42. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
    Tan, Chee-Seng, Cho, Byoung-Chul, Soo, Ross A. · 2016 · Lung Cancer
43. Tobacco Smoking and Lung Cancer : Perception Changing Facts = تدخين التبغ و سرطان الرئة : إدراك تغير الحقائق
    Muhammad Furrukh · 2013 · Sultan Qaboos University medical journal
44. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
    Douglas B. Johnson, Kimberly H Dahlman, Jared Knol, J. Gilbert, I. Puzanov, J. Means-Powell, J. Balko, C. Lovly, B. Murphy, L. Goff et al. · 2014 · The Oncologist
45. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
    Masahiko Yanagita, Amanda J. Redig, Cloud Peter Paweletz, Suzanne Eleanor Dahlberg, Allison O’Connell, Nora B. Feeney, Myriam Taibi, David H. Boucher, Geoffrey R. Oxnard, Bruce Evan Johnson et al. · 2016 · Clinical Cancer Research
46. Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I–IV Non-Small Cell Lung Cancer Patients
    Xiao Zhao, Rubing Han, Jing Zhao, Jun Wang, Fan Yang, Wei Zhong, Li Zhang, Longyun Li, Mengzhao Wang · 2012 · Respiration
47. Clinical application of amplicon-based next-generation sequencing in cancer
    Fengqi Chang, Marilyn M. Li · 2013 · Cancer Genetics
48. Diarrhea associated with afatinib: an oral ErbB family blocker
    James Chih‐Hsin Yang, Noemı́ Reguart, Jana Barinoff, Jens Köhler, Martina Uttenreuther‐Fischer, Uz M. Stammberger, Dennis O’Brien, Jürgen Wolf, Ezra E.W. Cohen · 2013 · Expert Review of Anticancer Therapy
49. Targeting MET Amplification as a New Oncogenic Driver
    Hisato Kawakami, Isamu Okamoto, Wataru Okamoto, Junko Tanizaki, Kazuhiko Nakagawa, Kazuto Nishio · 2014 · Cancers
50. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping
    Hye-Ryoun Kim, Sung Yong Lee, Dae-Sung Hyun, Min Ki Lee, Hyun-Kyung Lee, Chang‐Min Choi, Sei Hoon Yang, Young‐Chul Kim, Yong Chul Lee, Seon Young Kim et al. · 2013 · Journal of Experimental & Clinical Cancer Research
51. Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
    Takeshi Yoshida, Guolin Zhang, Matthew A. Smith, Alex S. Lopez, Yun Bai, Jiannong Li, Bin Fang, John M. Koomen, Bhupendra Rawal, Kate J. Fisher et al. · 2014 · Clinical Cancer Research
52. Rare cancers: a sea of opportunity
    Niki Boyd, Janet Ellen Dancey, C. Blake Gilks, David D. Huntsman · 2016 · The Lancet Oncology
53. MET Exon 14 Skipping in Non-Small Cell Lung Cancer
    Rebecca Suk Heist, Hyo Sup Shim, Shalini Gingipally, Mari A. Mino-Kenudson, Long P. Le, Justin F. Gainor, Zongli Zheng, Martin J. Aryee, Junfeng Xia, Peilin Jia et al. · 2016 · The Oncologist
54. Distinguishing prognostic and predictive biomarkers: an information theoretic approach
    Konstantinos Sechidis, Konstantinos Papangelou, Paul Metcalfe, David J. Svensson, James Weatherall, Gavin Brown B · 2018 · Computer applications in the biosciences
55. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
    Monique B. Nilsson, Yan Yang, Simon Heeke, Sonia A. Patel, Alissa Poteete, Hibiki Udagawa, Yasir Y. Elamin, César A. Moran, Yukie Kashima, Thiruvengadam Arumugam et al. · 2023 · Cancer Cell
56. Optimizing outcomes in <i>EGFR</i> Mutation-Positive Nsclc: Which Tyrosine Kinase Inhibitor and When?
    Girard, Nicolas · 2018 · Future Oncology
57. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
    Kunihiko Kobayashi, Koichi Hagiwara · 2013 · Targeted Oncology
58. Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
    Timothy Anthony Yap, Paul Workman · 2011 · The Annual Review of Pharmacology and Toxicology
59. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
    Koichi Azuma, Akihiko Kawahara, Kahori Sonoda, Kazutaka Nakashima, Kousuke Tashiro, Kosuke Watari, Hiroto Izumi, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono et al. · 2014 · Oncotarget
60. Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer
    Ivan Shterev Donev, Wei Wang, Tadaaki Yamada, Qi Li, Shinji Takeuchi, Kunio Matsumoto, Takao Yamori, Yasuhiko Nishioka, Saburo Sone, Seiji Yano · 2011 · Clinical Cancer Research
61. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer
    Hui Pan, Tao Jiang, Ningning Cheng, Qi Wang, Shengxiang Ren, Xuefei Li, Chao Zhao, Limin Zhang, Weijing Cai, Caicun Zhou · 2016 · Oncotarget
62. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management
    Xilin Sun, Zunyu Xiao, Gongyan Chen, Zhaoguo Han, Yang Liu, Chongqing Zhang, Yingying Sun, Yan Song, Kai Wang, Fang Fang et al. · 2018 · Science Translational Medicine
63. Management of co-existent tuberculosis and lung cancer
    Jcm Ho, Chi‐Chiu Leung · 2018 · Lung Cancer
64. Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer
    Shaohua Lu, Hui Kong, Yingyong Hou, Di Ge, Wei Huang, Jiaxian Ou, Dawei Yang, Li Zhang, Guoming Wu, Yong Song et al. · 2018 · Lung Cancer
65. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma
    Hyun Woo Chung, Kye Young Lee, Hee Joung Kim, Wan Seop Kim, Young So · 2013 · Journal of Cancer Research and Clinical Oncology
66. Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized, Phase II Study
    Ning Li, Wei Ou, Ye Xiong, Hai-bo Sun, Liang Zhang, Qin Fang, Song-Liang Zhang, Bao-Xiao Wang, Siyu Wang · 2014 · Annals of Surgical Oncology
67. Lung cancer: Prevalent trends & emerging concepts
    Vinod Raina, Prabhat Singh Malik · 2015 · The Indian Journal of Medical Research
68. How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples
    Takahiro Nakajima, Kazuhiro Yasufuku · 2010 · Journal of Thoracic Oncology
69. Use of molecular markers for predicting therapy response in cancer patients
    Michael Joe Duffy, Norma O’Donovan, John Paul Crown · 2010 · Cancer Treatment Reviews
70. Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness
    Owen Tan, Rupendra N. Shrestha, Michelle M. Cunich, DEBORAH J. SCHOFIELD · 2017 · Clinical Genetics
71. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients
    Kuo-Hsuan Hsu, Yen-Hsiang Huang, Jeng‐Sen Tseng, Kun‐Chieh Chen, Wen‐Hui Ku, Kang‐Yi Su, Jeremy J.W. Chen, Huei‐Wen Chen, Sung‐Liang Yu, Tsung‐Ying Yang et al. · 2018 · Lung Cancer
72. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
    Patrick R. Halliday, Collin Michael Blakely, Trever Grant Bivona · 2019 · Current Oncology Reports
73. Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials
    John Gregson, Linda D. Sharples, Gregg W. Stone, Carl‐Fredrik Burman, Fredrik Öhrn, Stuart Pocock · 2019 · Journal of the American College of Cardiology
74. The characterization of lung microbiome in lung cancer patients with different clinicopathology.
    Danhui Huang, Xiao-Fang Su, Man Yuan, Shujia Zhang, Jing He, Qiuhua Deng, Wenjun Qiu, Hangming Dong, Shaoxi Cai · 2019 · Europe PMC (PubMed Central)
75. Discovery of potent small molecule PROTACs targeting mutant EGFR
    Hongyi Zhao, Xueyan Yang, Hao Lei, Xiao-Xiao Xi, Shemin Lu, Junjie Zhang, Minhang Xin, San‐Qi Zhang · 2020 · European Journal of Medicinal Chemistry
76. Targeting EGFR Exon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates
    Catherine Belle Meador, Lecia Van Dam Sequist, Zofia Piotrowska · 2021 · Cancer Discovery
77. LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer
    Jiali Dai, Tianyu Qu, Dandan Yin, Yanan Cui, Chen Zhang, Erbao Zhang, Renhua Guo · 2023 · Cell Death and Disease
78. Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?
    Mok, Tony, Yang, Jin-Ji, Lam, Kwok-Chi · 2013 · Journal of Clinical Oncology
79. Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
    Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami, Shoichi Kuyama, Daizo Kishino, Masanori Fujii, Toshiyuki Kozuki, Masahiro Tabata, Daijiro Harada, Kenichi Chikamori et al. · 2015 · Journal of Thoracic Oncology
80. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
    Adam J. Atherly, D. Ross Camidge · 2012 · British Journal of Cancer
81. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
    Kenichi Nishie, Tomoya Kawaguchi, Akihiro Tamiya, Tomoyasu Mimori, Naoko Takeuchi, Yoshinobu Matsuda, Naoki Omachi, Kazuhiro Asami, Kyoichi Okishio, Shinji Atagi et al. · 2012 · Journal of Thoracic Oncology
82. Lung cancer in never smokers: Change of a mindset in the molecular era
    Young Ju Lee, Joo-Hang Kim, Soon Il Kim, Sang‐Jun Ha, Tony S.K. Mok, Tetsuya Mitsudomi, Byoung Chul Cho · 2011 · Lung Cancer
83. Prognostic value of site-specific metastases in lung cancer: A population based study
    Jing Li, Huaguang Zhu, Lei Sun, Wenqian Xu, Xin Wang · 2019 · Journal of Cancer
84. Treatment of Non-small Cell Lung Cancer with EGFR-mutations
    Kazue Yoneda, Naoko Imanishi, Yoshinobu Ichiki, Fumihiro Tanaka · 2019 · Journal of UOEH
85. Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway
    Yuhong Lü, Yanfeng Liu, Sebastian Oeck, Gary J. Zhang, Alexander R. Schramm, Peter M. Glazer · 2020 · Cancer Research
86. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy
    Arne Warth, Stephan Macher‐Goeppinger, Thomas Muley, Michael Thomas, Hans Hoffmann, Philipp Albert Schnabel, Roland Penzel, Peter Schirmacher, Sebastian Aulmann · 2011 · European Respiratory Journal
87. A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry
    Bárbara Angulo, Esther Conde, Ana Suárez‐Gauthier, Carlos Plaza, Rebeca Martínez, Pilar Redondo, Elisa Izquierdo, Belén Rubio‐Viqueira, Luis G Paz-Ares, Manuel M. Hidalgo et al. · 2012 · PLoS ONE
88. Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer
    Shuhang Wang, Tongtong An, Jie Wang, Jun Zhao, Zhijie Wang, Minglei Zhuo, Hua Bai, Lu Yang, Yan Zhang, Xin Wang et al. · 2010 · Clinical Cancer Research
89. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology
    Giulio Rossi, Maria Cecilia Mengoli, Alberto Cavazza, Davide Nicoli, Mattia Barbareschi, Chiara Cantaloni, Mauro Giulio Papotti, Andrea Tironi, Paolo Graziano, Massimiliano Paci et al. · 2013 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
90. Personalizing health care: feasibility and future implications
    Brian Godman, Alexander E. T. Finlayson, Parneet Kaur Cheema, Eva Maria Zebedin-Brandl, Iñaki Gutiérrez‐Ibarluzea, Jan Jones, Rickard E. Malmström, Elina Asola, Christoph Baumgärtel, Marion Bennie et al. · 2013 · BMC Medicine
91. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting
    Kōichi Goto, Miyako Satouchi, Genichiro Ishii, Kazuto Nishio, Koichi Hagiwara, Tetsuya Mitsudomi, Jessica L. Whiteley, Emma L. Donald, R. McCormack, Takuya Todo · 2012 · Annals of Oncology
92. The Impact of Genomic Changes on Treatment of Lung Cancer
    Stephanie Cardarella, Bruce Evan Johnson · 2013 · American Journal of Respiratory and Critical Care Medicine
93. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards
    Hakim‐Moulay Dehbi, Patrick J Royston, Allan K. Hackshaw · 2017 · BMJ
94. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies
    Ismail M. M. Othman, Zahra M. Al-Amshany, Nada Y. Tashkandi, Mohamed A. M. Gad‐Elkareem, Manal M. Anwar, Eman Samir Nossier · 2021 · Bioorganic Chemistry
95. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
    Damien Reita, Lucile Pabst, Erwan Pencreach, Éric Guérin, Laurent Dano, Valérie Rimelen, Anne‐Claire Voegeli, Laurent D. Vallat, Céline Mascaux, Michèle Beau‐Faller · 2021 · Cancers
96. Emerging evidence and treatment paradigm of non-small cell lung cancer
    Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si‐Yang Maggie Liu, Yangqiu Li, Yi-Long Lung Cancer Wu · 2023 · Journal of Hematology & Oncology
97. Targeted Therapies for Lung Cancer
    Jill E. Larsen, Tina Cascone, David E. Gerber, John Victor Heymach, John Dorrance Minna · 2011 · The Cancer Journal
98. Improvement of cellularity on cell block preparations using the so‐called tissue coagulum clot method during endobronchial ultrasound‐guided transbronchial fine‐needle aspiration
    Rex Chin Wei Yung, Susan Otell, Peter Bela Illei, Douglas P. Clark, David J Feller-Kopman, Lonny B. Yarmus, Frederic Barton Askin, Edward Gabrielson, Qing Kay Li · 2011 · Cancer Cytopathology
99. Pharmacogenomic biomarkers: new tools in current and future drug therapy
    Sarah C. Sim, Magnus Ingelman‐Sundberg · 2010 · Trends in Pharmacological Sciences
100. Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer
     Rita Nizzoli, Marcello Tiseo, Francesco Gelsomino, Marco Bartolotti, Maria Majori, Lilia Ferrari, Massimo De Filippo, Guido Rindi, Enrico Maria Silini, Annamaria Guazzi et al. · 2011 · Journal of Thoracic Oncology